Publication | Closed Access

Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial

Diabetes ManagementDiabetesPharmacologyClinical TrialsType 2PharmacotherapyOnce-weekly Semaglutide 2·4Diabetes MellitusMedicine